[1] Rahimizadeh, P., Rezaieyazdi, Z., Behzadi, F., Hajizade, A., & Lim, S. I. (2021). Nanotechnology as a promising platform for rheumatoid arthritis management: Diagnosis, treatment, and treatment monitoring. International Journal of Pharmaceutics, 609, 121137. https://doi.org/10.1016/j.ijpharm.2021.121137

[2] Aletaha, D., & Smolen, J. S. (2018). Diagnosis and management of rheumatoid arthritis: A review. Journal of the American Medical Association, 320(13), 1360–1372. https://doi.org/10.1001/jama.2018.13103

[3] Shakil, M., Saleem, D. M., Zafar, A., Ali, A., Raziq, M., & Shams, S. (2021). Clinical and hematological parameters in patients of Rheumatoid arthritis in a tertiary care hospital. Rawal Medical Journal, 46(1), 45–45.

[4] Khaliq, T., Khan, A., & Malik, I. A. (2020). Clinical profile and treatment outcomes of patients with rheumatoid arthritis at a tertiary care hospital of Pakistan. JPMA. The Journal of the Pakistan Medical Association, 70, 1143–1149. https://doi.org/10.5455/JPMA.289952

[5] Mittinty, M. M., Elliott, J. M., Hunter, D. J., Nicholas, M. K., March, L. M., & Mittinty, M. N. (2022). Explaining the gap in the experience of depression among arthritis patients. Clinical Rheumatology, 41(4), 1227–1233. https://doi.org/10.1007/s10067-021-06010-0

[6] Ashiq, K., Rehman, K., Ashiq, S., & Ahlam, S. (2017). Influence of osteoporosis on quality of life and current strategies for its management and treatment. GSC Biological and Pharmaceutical Sciences, 1(2), 34– 40.https://doi.org/10.30574/gscbps.2017.1.2.0051

[7] Yerima, A., Akintayo, R., & Adebajo, A. (2021). Implications of a diagnosis of rheumatoid arthritis in resource-poor countries. Best Practice & Research Clinical Rheumatology. https://doi.org/10.1016/j.berh.2021.101725

[8] Clayton, S. A., MacDonald, L., Kurowska-Stolarska, M., & Clark, A. R. (2021). Mitochondria as key players in the pathogenesis and treatment of rheumatoid arthritis. Frontiers in Immunology, 12, 1488. https://doi.org/10.3389/fimmu.2021.673916

[9] McInnes, I. B., & Schett, G. (2017). Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet, 389(10086), 2328–2337. https://doi.org/10.1016/S0140- 6736(17)31472-1

[10] Mueller, A. L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021). Recent advances in understanding the pathogenesis of rheumatoid arthritis: New treatment strategies. Cells, 10(11), 3017. https://doi.org/10.3390/cells10113017

[11] Tobón, G. J., Youinou, P., & Saraux, A. (2010). The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. Autoimmunity Reviews, 9(5), A288– A292. https://doi.org/10.1016/j.autrev.2009.11.019

[12] Otón, T., & Carmona, L. (2019). The epidemiology of established rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology, 33(5), 101477. https://doi.org/10.1016/j.berh.2019.101477

[13] Podgórska, D., Cieśla, M., Kolarz, B. (2022). FCER1G gene hypomethylation in patients with rheumatoid arthritis. Journal of Clinical Medicine, 11(16), 4664.

[14] Fang, Q., Ou, J., & Nandakumar, K. S. (2019). Autoantibodies as diagnostic markers and mediator of joint inflammation in arthritis. Mediators of Inflammation, 2019, 6363086. Advance online publication. https://doi.org/10.1155/2019/6363086

[15] Harre, U., Lang, S. C., Pfeifle, R., Rombouts, Y., Frühbeißer, S., Amara, K., Bang, H., Lux, A., Koeleman, C. A., Baum, W., Dietel, K., Gröhn, F., Malmström, V., Klareskog, L., Krönke, G., Kocijan, R., Nimmerjahn, F., Toes, R. E., Herrmann, M., . . . Schett, G. (2015). Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nature Communications, 6(1), 6651. https://doi.org/10.1038/ncomms7651

[16] Burmester, G. R., Feist, E., & Dörner, T. (2014). Emerging cell and cytokine targets in rheumatoid arthritis. Nature Reviews Rheumatology, 10(2), 77–88. https://doi.org/10.1038/nrrheum.2013.168

[17] McInnes, I. B., Buckley, C. D., & Isaacs, J. D. (2016). Cytokines in rheumatoid arthritis – Shaping the immunological landscape. Nature Reviews Rheumatology, 12(1), 63–68. https://doi.org/10.1038/nrrheum.2015.171

[18] Fang, Q., Zhou, C., & Nandakumar, K. S. (2020). Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators of Inflammation, 2020, 3830212. Advance online publication. https://doi.org/10.1155/2020/3830212

[19] Tuna, H. I., Alparslan, G. B., & Yilmaz, S. (2022). Pain and affected symptoms of patients with rheumatoid arthritis during COVID-19 period. Pain Management Nursing, 23(1), 43–47. https://doi.org/10.1016/j.pmn.2021.08.004

[20] Chancay, M. G., Guendsechadze, S. N., & Blanco, I. (2019). Types of pain and their psychosocial impact in women with rheumatoid arthritis. Women’s Midlife Health, 5(1), 3. https://doi.org/10.1186/s40695-019-0047-4

[21] Kaptoge, S., Di Angelantonio, E., Pennells, L., Wood, A. M., White, I. R., Gao, P., Walker, M., Thompson, A., Sarwar, N., Caslake, M., Butterworth, A. S., Amouyel, P., Assmann, G., Bakker, S. J., Barr, E. L., Barrett-Connor, E., Benjamin, E. J., Björkelund, C., Brenner, H., . . . Danesh, J., & the Emerging Risk Factors Collaboration. (2012). C-reactive protein, fibrinogen, and cardiovascular disease prediction. The New England Journal of Medicine, 367(14), 1310–1320. https://doi.org/10.1056/NEJMoa1107477

[22] Kaushik, P., Solomon, D. H., Greenberg, J. D., Anderson, J. T., Reed, G., Pala, O., Sumbul-Yuksel, B., Kadam, P., Kremer, J. M., & the CORRONA investigators. (2015). Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: Results from a large US registry. Clinical Rheumatology, 34(10), 1697–1704. https://doi.org/10.1007/s10067-015-3032-9

[23] Lin, Y. J., Anzaghe, M., & Schülke, S. (2020). Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells, 9(4), 880. https://doi.org/10.3390/cells9040880

[24] do Prado, A. D., Staub, H. L., Bisi, M. C., da Silveira, I. G., Mendonça, J. A., Polido- Pereira, J., & Fonseca, J. E. (2018). Ultrasound and its clinical use in rheumatoid arthritis: Where do we stand? Advances in Rheumatology (London, England), 58, 19. Advance online publication. https://doi.org/10.1186/s42358-018-0023-y

[25] Takase-Minegishi, K., Horita, N., Kobayashi, K., Yoshimi, R., Kirino, Y., Ohno, S., Kaneko, T., Nakajima, H., Wakefield, R. J., & Emery, P. (2018). Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: Systematic review and meta-analysis. Rheumatology (Oxford, England), 57(1), 49–58. https://doi.org/10.1093/rheumatology/kex036

[26] Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., III, Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., Combe, B., Costenbader, K. H., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M., Hobbs, K., Huizinga, T. W., Kavanaugh, A., . . . Hawker, G. (2010). 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 62(9), 2569– 2581. https://doi.org/10.1002/art.27584

[27] Akram, M., Daniyal, M., Sultana, S., Owais, A., Akhtar, N., Zahid, R., Said, F., Bouyahya, A., Ponomarev, E., Ali Shariat, M., & Thiruvengadam, M. (2021). Traditional and modern management strategies for rheumatoid arthritis. Clinica Chimica Acta, 512, 142–155. https://doi.org/10.1016/j.cca.2020.11.003

[28] Ruffer, N., Krusche, M., Beil, F. T., Amling, M., Kötter, I., & Rolvien, T. (2022). Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: A systematic review. Seminars in Arthritis and Rheumatism, 52, 151952. https://doi.org/10.1016/j.semarthrit.2022.151952

[29] Paglia, M. D. G., Silva, M. T., Lopes, L. C., Barberato-Filho, S., Mazzei, L. G., Abe, F. C., & de Cássia Bergamaschi, C. (2021). Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One, 16(4), e0248866. https://doi.org/10.1371/journal.pone.0248866

[30] Hua, C., Buttgereit, F., & Combe, B. (2020). Glucocorticoids in rheumatoid arthritis: Current status and future studies. RMD Open, 6(1), e000536. https://doi.org/10.1136/rmdopen-2017-000536

[31] Ashiq, K., Bajwa, M. A., Khokhar, R., Abid, F., Tanveer, S., Qayyum, M., Ashiq, S., & Jameel, S. (2022). A Cross-sectional analysis of knowledge, beliefs and practices regarding traditional medicine use among pharmacy students of different private and government universities of Lahore, Pakistan. Bangladesh Journal of Medical Science, 21(2), 323–334. https://doi.org/10.3329/bjms.v21i2.58065

[32] Chaudhary, A., & Vinay, P. (2020). Rheumatoid arthritis: Etiology, treatment and animal models. Journal of Drug Delivery and Therapeutics, 10(no. 5-s), 290–298. https://doi.org/10.22270/jddt.v10i5-s.4357

[33] Sarsenova, M., Issabekova, A., Abisheva, S., Rutskaya-Moroshan, K., Ogay, V., & Saparov, A. (2021). Mesenchymal stem cell-based therapy for rheumatoid arthritis. International Journal of Molecular Sciences, 22(21), 11592. https://doi.org/10.3390/ijms222111592

[34] Ashiq, K., Bajwa, M. A., Tanveer, S., Qayyum, M., Ashiq, S., Khokhar, R., & Abid, F. (2021). A comprehensive review on gout: The epidemiological trends, pathophysiology, clinical presentation, diagnosis and treatment. JPMA. The Journal of the Pakistan Medical Association, 71(4), 1234–1238. https://doi.org/10.47391/JPMA.313

[35] Babar, Z. U. D. (2022). Forming a medicines pricing policy for low and middleincome countries (LMICs): The case for Pakistan. Journal of Pharmaceutical Policy and Practice, 15(1), 9. https://doi.org/10.1186/s40545-022-00413-3